Intravenous dolasetron mesilate ameliorates postoperative nausea and vomitingPurpose: To compare the efficacy, safety, and tolerability of dolasetron mesilate with placebo for the treatment of postoperative nausea and vomiting (PONV), Methods: In a randomized, multicentre, double-blind, placebo-controlled study 337 adult patients undergoing surgery with general anaesthesia received one of four single, doses of dolasetron mesilate iv (I 2.5, 25, 50, or I00 mg) or placebo, Study medication was administered postoperatively when the patient reported nausea lasting 10 rain or when one emetic episode occurred within two hours of the patient's arrival in the recovery room. Efficacy was assessed by the investigators over the 24-hr study period by recording the number and timing of emetic episodes, the severity of nausea, the timing of administration of escape antiemetic medications, and patients' and investigators' satisfaction with antiemetic therapy, Results: The study sample was predominately women, and the surgical procedures were primarily gynaecological, All dolasetron mesilate doses produced higher complete response rates than placebo (P<0.05). Only approximately one-third of dolasetron patients required escape antiemetic medication compared with more than 50% of patients in the placebo group, Both patient and physician satisfaction with dolasetron treatment was high. The most common adverse event was mild or moderate headache for both placebo-treated patients and dolasetron-treated patients, Clinical laboratory results were unremarkable. Conclusion: Single doses of dolasetron mesilate iv, given after the first episode of PONV, were both effective and safe in this adult patient population.Objectif : Comparer I'efficacit6, la s6curit6 et I'acceptabilit6 du m6silate de dolasetron avec celles d'un placebo pour le traitement des naus6es et vomissements postop6ratoires (NVPO). M~thodes : Au cours d'une 6rude multicentrique, en double aveugle, contr616e par placebo, 337 adultes soumis ~ une chirurgie sous anesth~sie g6n~rale ont regu du m6silate de dolasetron ~ une de quatre posologies iv (I 2,5, 25, 50, ou 100 mg) ou un placebo. Le m6dicament 6tait administr6 en postoperatoire Iorsque le patient se plaignait d'une naus6e de dur~e I0 min ou quand au moins en 6pisode 6m~tique survenait au cours des deux heures suivant I'arriv6e du patient en salle de r6veil, Sur une p6riode d'6tude de 24 h, I'efficacit6 etait 6valu6e par les investigateurs par I'enregistrement du nombre et de la chronologie des 6pisodes, la gravit6 de la naus6e, le temps de I'administration de la m6dication anti~m&ique de rattrapage, et la satisfaction du patient ou de I'investigateur envers le traitement. R~sultats : 126chantillon de la population 6tudi6e comprenait surtout des femmes et les interventions 6taient surtout gyn6cotogiques. Toutes les doses de m6silate de dotasetron procuraient une r6ponse complete plus fr6quente que le placebo (P <0,05), Seulement un tiers environ des patients sous dolasetron ont eu besoin d'un m~dicament anti6m6tique de ...
SummarySixty unpremedicated children aged between 3 and 14 years, scheduledfor otoplasty , were randomly divided into one of three groups to receive either ondansetron 0.1 mg.kg-I, droperidol 75pgg.kg-', or placebo at induction of anaesthesia. All patients received a standard general anaesthetic using thiopentone, atracurium and halothane. Opioid analgesia was avoided intra-operatively and injiltration with local anaesthetic was usedprior to the start of surgery. Children who received ondansetron were less likely to vomit (15%) than those who received either droperidol (40%) or placebo (60%) (j < 0.01). This group also tolerated oral ingestion of fluids andsolids earlier than those who receivedeither droperidol or placebo (j < 0.001). There wasno dijierence between the placebo or droperidol group in the incidence of vomiting or time to ingestion of oral fluids and meals. Three patients in the ondansetron group had a self terminating nodal rhythm which was not associated with any haemodynamic disturbances. Postoperatively there were no untoward incidents in any of the groups and all patients were discharged home the day after surgery.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with đź’™ for researchers
Part of the Research Solutions Family.